Antares Therapeutics

Private

#Autoimmune Disease #Inflammation #Immunology

Antares Therapeutics is a clinical-stage small molecule biopharmaceutical company developing oral and injectable therapies for autoimmune and inflammatory diseases. The company is headquartered in Princeton, New Jersey, and was acquired by Novartis in 2026.

Company Info

Sector:Small Molecule Therapeutics

Headquarters:Princeton, New Jersey, USA

Founded:2020

Website:antaresrx.com/

Funding Round:Acquired by Novartis (2026)

Total Funding:Undisclosed (acquisition terms)

Funding & Investor Relations

IPO Outlook / Plans

N/A (private; acquired)

Upcoming Milestones & Key Dates

2026-07-15

Clinical Readout

Phase 2 ATRS-101 topline readout (psoriasis)

2026-11-08

Conference

AHA Scientific Sessions

Clinical Development Pipeline

ATRS-101

Target: TYK2 inhibitor

Plaque psoriasis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ATRS-202

Target: JAK1-selective

Rheumatoid arthritis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ATRS-303

Target: Allosteric S1P receptor modulator

Inflammatory bowel disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies ↗

Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies.

Leadership Team

Amitabh Singh

Chief Executive Officer

Robert Forrester

Chief Operating Officer

Marianne C. Rotschafer

Chief Medical Officer

Careers & Job Openings

See all open roles

Various

Apply Now →